KFU. Card publication. Pathogenesis, Diagnosis, and Treatment of Hemostatic Disorders in COVID-19 Patients

KAZAN
FEDERAL UNIVERSITY

- RUS
- 中文
- ES

PATHOGENESIS, DIAGNOSIS, AND TREATMENT OF HEMOSTATIC DISORDERS IN COVID-19 PATIENTS

Form of presentation

Articles in international journals and collections

Year of publication

2021

��

��

Authors, employees of KFU

Zinchenko Sergey Viktorovich, author

Kiyasov Andrey Pavlovich, author

Litvinov Rustem Igorevich, author

Rizvanov Albert Anatolevich, author

Sharafeev Aydar Zaytunovich, author

Bibliographic description in the original language

Khalirakhmanov A.F. Pathogenesis, Diagnosis, and Treatment of Hemostatic Disorders in COVID-19 Patients/A.F. Khalirakhmanov, K.F. Idrisova, R.F. Gaifullina, S.V. Zinchenko, R. I. Litvinov, A. Z. Sharafeev, A. P. Kiyasov, A. A. Rizvanov//Acta Naturae. - 2021. - Vol.13, Is.2. - P.79-84.

Annotation

The novel coronavirus infection named COVID-19 was first detected in Wuhan, China, in December 2019, and it has been responsible for significant morbidity and mortality in scores of countries. At the time this article was being written, the number of infected and deceased patients continued to grow worldwide. Most patients with severe forms of the disease suffer from pneumonia and pulmonary insufficiency; in many cases, the disease is generalized and causes multiple organ failures and a dysfunction of physiological systems. One of the most serious and prognostically ominous complications from COVID-19 is coagulopathy, in particular, decom - pensated hypercoagulability with the risk of developing disseminated intravascular coagulation. In most cases, local and diffuse macro- and microthromboses are present, a condition which causes multiple-organ failure and thromboembolic complications. The causes and pathogenic mechanisms of coagulopathy in COVID-19 remain largely unclear, but they are associated with systemic inflammation, including the so-called cytokine storm. De - spite the relatively short period of the ongoing pandemic, laboratory signs of serious hemostatic disorders have been identified and measures for specific prevention and correction of thrombosis have been developed. This review discusses the causes of COVID-19 coagulopathies and the associated complications, as well as possible approaches to their early diagnosis, prevention, and treatment.

Keywords

coronavirus, hemostatic disorders, thrombosis, anticoagulants, cytokine storm, COVID-19

The name of the journal

ACTA NATURAE

URL

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112813553&doi=10.32607%2factanaturae.11182&partnerID=40&md5=6e2d644d842a9d146b14d7edcda9d5fe

Please use this ID to quote from or refer to the card

https://repository.kpfu.ru/eng/?p_id=255770&p_lang=2

Resource files

File name	Size (MB)	Format
Acta_Nature__1_.pdf	0,15	pdf	show / download

Full metadata record

Field DC	Value	Language
dc.contributor.author	Zinchenko Sergey Viktorovich	ru_RU
dc.contributor.author	Kiyasov Andrey Pavlovich	ru_RU
dc.contributor.author	Litvinov Rustem Igorevich	ru_RU
dc.contributor.author	Rizvanov Albert Anatolevich	ru_RU
dc.contributor.author	Sharafeev Aydar Zaytunovich	ru_RU
dc.date.accessioned	2021-01-01T00:00:00Z	ru_RU
dc.date.available	2021-01-01T00:00:00Z	ru_RU
dc.date.issued	2021	ru_RU
dc.identifier.citation	Khalirakhmanov A.F. Pathogenesis, Diagnosis, and Treatment of Hemostatic Disorders in COVID-19 Patients/A.F. Khalirakhmanov, K.F. Idrisova, R.F. Gaifullina, S.V. Zinchenko, R. I. Litvinov, A. Z. Sharafeev, A. P. Kiyasov, A. A. Rizvanov//Acta Naturae. - 2021. - Vol.13, Is.2. - P.79-84.	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/eng/?p_id=255770&p_lang=2	ru_RU
dc.description.abstract	ACTA NATURAE	ru_RU
dc.description.abstract	The novel coronavirus infection named COVID-19 was first detected in Wuhan, China, in December 2019, and it has been responsible for significant morbidity and mortality in scores of countries. At the time this article was being written, the number of infected and deceased patients continued to grow worldwide. Most patients with severe forms of the disease suffer from pneumonia and pulmonary insufficiency; in many cases, the disease is generalized and causes multiple organ failures and a dysfunction of physiological systems. One of the most serious and prognostically ominous complications from COVID-19 is coagulopathy, in particular, decom - pensated hypercoagulability with the risk of developing disseminated intravascular coagulation. In most cases, local and diffuse macro- and microthromboses are present, a condition which causes multiple-organ failure and thromboembolic complications. The causes and pathogenic mechanisms of coagulopathy in COVID-19 remain largely unclear, but they are associated with systemic inflammation, including the so-called cytokine storm. De - spite the relatively short period of the ongoing pandemic, laboratory signs of serious hemostatic disorders have been identified and measures for specific prevention and correction of thrombosis have been developed. This review discusses the causes of COVID-19 coagulopathies and the associated complications, as well as possible approaches to their early diagnosis, prevention, and treatment.	ru_RU
dc.language.iso	ru	ru_RU
dc.subject	coronavirus	ru_RU
dc.subject	hemostatic disorders	ru_RU
dc.subject	thrombosis	ru_RU
dc.subject	anticoagulants	ru_RU
dc.subject	cytokine storm	ru_RU
dc.subject	COVID-19	ru_RU
dc.title	Pathogenesis, Diagnosis, and Treatment of Hemostatic Disorders in COVID-19 Patients	ru_RU
dc.type	Articles in international journals and collections	ru_RU